Partner News: Artyc Launches Medstow Mini for Temperature Stable Blood Sample Collection and Delivery
Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc’s Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.
Tasso and UBC Partner to Advance Decentralized Sample Collection and Analysis Solutions for Post-Approval Research
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.
Partner News: Aptar Digital Health and Tasso Combine Capabilities to Facilitate Blood Sample Collection for Multiple Indications Including Chronic Conditions and Oncology
Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, and Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today entered into a collaboration to offer Aptar Digital Health end-users access to Tasso’s devices for blood collection. The collaboration will focus on improving patient care through a simplified and integrated experience, delivering clinical value to patients through a real-world deployment and increasing adoption of new technologies by patients, providers and pharmaceutical companies.
Partner News: CardioRenal receives FDA Breakthrough Device Designation for TENOR
CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), today announces that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
Tasso Recommended for Certification from Medical Device Single Audit Program (MDSAP)
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that it has been recommended for certification from the Medical Device Single Audit Program (MDSAP), under which a single regulatory audit of a medical device manufacturer may satisfy the requirements of multiple regulatory jurisdictions participating in the program. The certification confirms Tasso’s compliance with the standards and regulatory requirements of Australia, Canada and the United States, opening potential new global markets for Tasso.
Tasso, Inc. Announces Duncan Porter as Senior Vice President of Growth
Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection technology, today announced the appointment of Duncan Porter as Senior Vice President of Growth, reporting to Tasso’s CEO Ben Casavant. Porter will lead Tasso's international expansion, building upon the recent CE regulatory approval of their TassoOneTM Plus and Tasso-M20 devices.
Tasso High-Volume Liquid Blood Collection Device Earns CE Mark Certification
Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TassoOne Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
Catapult Health and Tasso Join Forces to Create Convenient, Patient-Centric Preventive Care Solution for Fortune 500 Employers and National Health Plans
Catapult Health, a virtual preventive care provider serving 3,500 employers with over 2 million covered lives, and Tasso Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced a collaboration that will simplify home-based preventive care for employees and their families. Effective October 5th, Catapult will start offering the Tasso+™ device as part of its VirtualCheckup, an innovative at-home annual wellness checkup that combines simple and virtually painless testing with face-to-face clinical video consultations.
Tasso+™ Device Earns FDA 510(k) Class II Medical Device Clearance
Tasso, Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+™ lancet as a Class II medical device. The clearance allows the company to market and sell the device to more pharmaceutical companies, healthcare organizations, and academic institutions across the country, expanding access to a simple and virtually painless blood collection experience.
Tasso Launches Integrated Population Pharmacokinetic Solutions to Optimize, Scale, and Accelerate Decentralized Clinical Trials
Tasso, Inc., a leader in clinical-grade blood collection solutions, today announced the launch of Tasso PopPK Solutions, an integrated patient-centric offering for Population Pharmacokinetics (“PopPK”). With the launch of Tasso PopPK Solutions, Tasso now enables pharmaceutical companies to operationalize pharmacokinetic studies as part of their decentralized clinical trial efforts. Tasso's remote, patient-centric solution supports the acquisition of scalable and convenient pharmacokinetic data, improving modeling accuracy and accelerating clinical trials.
Fierce Medtech names Tasso as one of its “Fierce 15” Med Tech Companies of 2021
Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
Vault Health and Tasso Partner for Expansion of Patient-Centric At-Home Diagnostics
Vault Health, an innovative healthcare company bringing virtual care to millions, today announced a partnership with Tasso, Inc., a leader in simple clinical grade blood collection technology, to integrate Tasso products and logistics into Vault’s turnkey service offering. The new partnership will enable an improved, virtually painless sample collection experience for Vault customers.
Tasso secures $100M in Series B financing
Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million. The financing round was led by RA Capital Management and included participation from new investors the D.E. Shaw group, Senvest, InCube, and SVB Innovation Fund, as well as existing investors Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai, and Merck GHIF.
InnoVero and Tasso Partner to Provide Non-Invasive, Athlete-Centric Solutions for Anti-Doping Testing
InnoVero LLC, maker of the innovative SAFESystem™ sample collection kit currently revolutionizing global anti-doping practices, today announced a partnership with Tasso, Inc. to become the exclusive worldwide distributor for Tasso blood collection devices for the anti-doping marketplace. The partnership will accelerate global efforts to expand consistent non-invasive anti-doping testing.
Tasso-M20 Device Earns CE Mark Certification for At-Home, Self-Sampling Blood Collection
Tasso Inc., a pioneer in clinical-grade, at-home, self-sampling blood collection, today announced that its Tasso-M20 device has received a CE (Conformité Européene) Mark certification and has successfully fulfilled all of the European Union’s performance, safety, and relevant product requirements. With this marking, Tasso is now able to provide pharmaceutical companies, leading medical institutions, and government health centers across the European Union and other CE Mark geographies with a best-in-class diagnostic experience for their patients.
Tasso Secures $17 Million Series A Financing to Scale Production of At-Home Blood Collection Systems and Capitalize on Growing Demand for Remote Diagnostic Testing
Tasso Inc., a pioneer in clinical-grade, at-home, self-sampling blood collection, today announced it has completed an oversubscribed $17 million Series A financing round. The company will use the proceeds to scale manufacturing and operations to meet the increased demand for its line of innovative Tasso OnDemand devices, which enable people to collect their own blood using a virtually painless process from anywhere at any time. These fast and easy-to-use products are being adopted by leading academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations around the world.
Tasso Raises $6.1M to Bring Effortless Blood Collection into the Home
Tasso, Inc. has completed a $6.1 million round of financing led by Vertical Venture Partners (“VVP”), with participation from Techstars and Cedars-Sinai. This new funding will help Tasso scale its first product Tasso OnDemand, which enables at-home self-collection of blood samples, and grow the team to support significant commercial interest.
Tasso and partners receive $4.25M to develop a universal surveillance platform for infectious disease outbreaks
Tasso, Inc. (Tasso), Ceres Nanosciences (Ceres), George Mason University (Mason), and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) today announced the commencement of an $11.7 million program, funded by the Defense Threat Reduction Agency (DTRA), to develop a reliable, safe, and simple universal surveillance platform for infectious disease outbreaks.
Tasso simplifies blood draws, awarded $3M expansion
Tasso, Inc., a medtech start-up developing the HemoLink™, a small disposable device to simplify blood sampling, has secured an additional $2.9M in grant funding to advance its HemoLink technology with its development partner GenTegra LLC.